Sol-Gel Technologies (SLGL) Share-based Compensation (2015 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Share-based Compensation of $100000.0 for Q2 2025, down 63.64% year-over-year from $275000.0 in Q2 2024, and down 63.64% quarter-over-quarter from $275000.0 in Q2 2024.
Analysis
Sol-Gel Technologies (SLGL) Share-based Compensation (2015 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Share-based Compensation for 8 consecutive years, with $100000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Share-based Compensation fell 63.64% year-over-year to $100000.0; the TTM figure through Jun 2025 stood at $1.2 million (down 8.45% YoY), while the FY2025 annual figure was $82000.0, down 89.57% from the prior year.
- Share-based Compensation slipped to $100000.0 in Q2 2025 per SLGL's latest filing, from $275000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $498000.0 in Q2 2023 and bottomed at $100000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $287600.0 across 5 years, with a median of $275000.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 65.26% — and 2025, when it slumped 63.64%.
- Sol-Gel Technologies' Share-based Compensation stood at $213000.0 in 2021, then surged by 65.26% to $352000.0 in 2022, then surged by 41.48% to $498000.0 in 2023, then slumped by 44.78% to $275000.0 in 2024, then plunged by 63.64% to $100000.0 in 2025.
- Business Quant data shows SLGL's Share-based Compensation at $100000.0 in Q2 2025, $275000.0 in Q2 2024, and $498000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 154,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 154,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Dec 31, 2018 | 2.93 Mn |
| Dec 31, 2017 | 849,780.00 |
| Dec 31, 2016 | 402,955.00 |
| Dec 31, 2015 | 312,194.00 |